View Older Stories View More Recent Stories
-
Scholar Rock (SRRK) PT Lowered to $48 at Leerink Partners
-
Scholar Rock (SRRK) PT Lowered to $44 at Barclays
-
FDA rejects Scholar Rock's apitegromab application due to facility issues
-
Scholar Rock Holding Corp. (SRRK) Halted, News Pending
-
Barclays Starts Scholar Rock (SRRK) at Overweight
-
Leerink Partners Starts Scholar Rock (SRRK) at Outperform
-
Jefferies Assumes Scholar Rock (SRRK) at Buy
-
Raymond James Adjusts Analysts Current Favorites List
-
Scholar Rock (SRRK) PT Lowered to $45 at BMO Capital
-
Raymond James Reiterates Strong Buy Rating on Scholar Rock (SRRK)
-
Scholar Rock Holding Corp. (SRRK) Misses Q2 EPS by 32c
-
Raymond James Assumes Scholar Rock (SRRK) at Strong Buy
-
Cantor Fitzgerald Starts Scholar Rock (SRRK) at Overweight
-
Truist Securities Reiterates Buy Rating on Scholar Rock (SRRK)
-
H.C. Wainwright Reiterates Buy Rating on Scholar Rock (SRRK)
-
Scholar Rock Holding (SRRK) Reports Positive Phase 2 EMBRAZE Trial Results Demonstrating Statistically Significant Preservation of Lean Mass with Apitegromab During Tirzepatide-Induced Weight Loss
-
Jefferies: 'We highlight multiple de-risked or commercial-stage names that we think have promising M&A potential'
-
Scholar Rock Holding Corp. (SRRK) Appoints as Rebecca McLeod Chief Brand Officer and U.S. General Manager
-
Scholar Rock Holding Corp. (SRRK) Misses Q1 EPS by 1c
-
Truist Securities Reiterates Buy Rating on Scholar Rock (SRRK)
-
Scholar Rock Holding Corp. (SRRK) Appoints David L. Hallal as CEO
-
Piper Sandler: 'Scholar Rock (SRRK) Shares are Significantly Undervalued'
-
Truist Weighs In on Obesity: 'Catalyst-Rich 2025 Ahead in a Growing Competitive Landscape'
-
Truist Securities Reiterates Buy Rating on Scholar Rock (SRRK)
-
Scholar Rock Holding Corp. (SRRK): FDA Grants Priority Review for BLA and EMA Accepts MAA for Apitegromab as a Treatment for SMA
-
Scholar Rock Holding Corp. (SRRK) announces employee inducement grants
-
Scholar Rock Holding Corp. (SRRK) spreader of 1K contracts of April 45 and 60 calls
-
Scholar Rock Holding Corp. (SRRK) Misses Q4 EPS by 189c
-
Truist Reiterates Buy Rating on Scholar Rock (SRRK) Ahead of EMBRAZE Data
-
Scholar Rock Holding Corp. (SRRK) Submits BLA to the U.S. FDA for Apitegromab as a Treatment for Patients with SMA
-
Scholar Rock Holding Corp. (SRRK) Highlights 2025 Strategic Priorities
-
Biopharma 2025 Preview: 'Piper Sandler Sees Lots of Upside Opportunity'
-
Scholar Rock (SRRK) PT Raised to $50 at H.C. Wainwright
-
Scholar Rock Holding (SRRK) +33% today after Biohaven’s SMA study update miss
-
Scholar Rock (SRRK) PT Raised to $45 at Truist Securities on Biohaven's data miss
-
Scholar Rock (SRRK) PT Raised to $39 at BMO Capital
-
Scholar Rock (SRRK) PT Raised to $40 at H.C. Wainwright
-
Scholar Rock Holding Corp. (SRRK) Misses Q3 EPS by 8c
-
Truist Securities Reiterates Buy Rating on Scholar Rock (SRRK)
-
Scholar Rock (SRRK) PT Raised to $42 at Piper Sandler
-
Scholar Rock (SRRK) PT Raised to $38 at BMO Capital
-
Scholar Rock Holding Corp. (SRRK) Prices Upsized 10.27M Share and Warrant Offering at $28.25/sh
-
Scholar Rock (SRRK) PT Raised to $35 at H.C. Wainwright
-
Scholar Rock Holding Corp. (SRRK) call put ratio 1 call to 2.4 puts
-
After-hours movers: PENN Entertainment, Scholar Rock, and more
-
Scholar Rock Holding Corp. (SRRK) Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
-
Scholar Rock Holding Corp. (SRRK) Files Mixed Shelf
-
TD Cowen Reiterates Buy Rating on Scholar Rock (SRRK)
-
Scholar Rock (SRRK) PT Raised to $36 at Truist Securities
-
Scholar Rock (SRRK) Reports Apitegromab Meets Primary Endpoint in Phase 3 SAPPHIRE Study in Patients with Spinal Muscular Atrophy
